MicroRNA-429 inhibits cancer cell proliferation and migration by targeting the AKT1 in melanoma

Abstract

MicroRNAs (miRNAs; miR) have been proven to act as both oncogenes and tumor suppressors. However, the mechanism of action of miR429 in melanoma cells remains to be elusive. The present study aims to explain the functional role and mechanism of miR429 in the pathogenesis of melanoma. In our study, we have demonstrated that has-miRNA429 (miR429) is a tumor suppressor in melanoma cells. Luciferase reporter assays demonstrated that the overexpression of miR429 reduced the transcriptional activity of AKT serine/threonine kinase 1 (AKT1). Furthermore, the results showed that the mRNA and protein expression levels of AKT1 were downregulated in the melanoma cell lines when miR429 was overexpressed according to qRT-PCR and western bolt, indicating MicroRNA-429 may directly target AKT1 in melanoma. In vivo, overexpression miR-429 could obviously enhance the inhibition effect of tumor size and weight in the nude mice. Taken together, our findings suggest that novel miR429-regulated pathway may serve as new insights into melanoma oncogenesis and metastasis.

Keywords

Melanoma cells AKT1 miR429

1. Introduction

Malignant melanoma is an aggressive tumor with increasing incidence and poor prognosis in the metastatic stage [1]. Although many genetic and epigenetic changes are found to be correlated with melanoma, the carcinogenesis remains poorly understood [2].

MicroRNAs (miRNAs) are endogenous small ncRNA of 19–22 nucleotides that regulate gene expressions. They regulate protein-coding gene expressions at the post-transcriptional level through translational inhibition or mRNA degradation [3]. It is wildly accepted that miRNAs are distributed in some cancers [4, 5, 6], and dysregulate key processes of tumor development and progression, including proliferation, differentiation, cell cycle, apoptosis, migration and invasion [7, 8].

miR429, a member of the miR-200 family, has been recently identified to be an oncogene or tumorsuppressor gene in diverse cancers, including ovarian cancer [9], cervical cancer [10], cholangiocarcinoma [11], non-small cell lung cancer [12], gastric cancer [13], hepatocellular carcinoma [14]. Wu et al. [15] have found that miR429 in RCC contributed to cell migration, cell survival and invasion via the downregulation of Sp1. Chen et al. [16] have also demonstrated that miR429 can regulate RCC cell function by targeting VEGF and reduce the 3’UTR luciferase action of VEGF. However, the role and mechanisms of miR-429 in melanoma cells have not been illustrated clearly. In the present study, we identified AKT1 as a target of miR-429 and showed the possibility of miR-429/AKT1-mediated signal pathway as a new target for melanoma treatment.

Table 1
Primer sequences used in the present study

Primer	Sequence
AKT1 (forward)	AGCGACGTGGCTATTGTGAAG
AKT1 (reverse)	GCCATCATTCTTGAGGAGGAAGT
AKT1-3’UTR-WT (forward)	ACGCGTGCTAGCCCGGGCGAGCCCAGATGGAAAGACGT
AKT1-3’UTR-WT (reverse)	GCAGATCGCAGATCTCGAATTTGGAGGGAAGGTTCCA
AKT1-3’UTR-MUT (forward)	TTTACAACATTCAACTTCGAAGAGCTTACTATTATAATATAATA
AKT1-3’UTR-MUT (reverse)	TATTATATTATAATAGTAAGCTTCACGAAGTTGAATGTTGTAAA
miR-429 mimic (forward)	UAAUACUGUCUGGUAAAACCGU
miR-429 mimic (reverse)	GGUUUUACCAGACAGUAUUAUU
NC mimic (forward)	UUCUCCGAACGUGUCACGUUT
NC mimic (reverse)	ACGUGACACGUUCGGAGAATT
GAPDH (forward)	GGAGCGAGATCCCTCCAAAAT
GAPDH (reverse)	GGCTGTTGTCATACTTCTCATGG

3’UTR, 3’ untranslated region; WT, wild-type; MUT, mutant.

2. Materials and methods

2.1 Cell culture

A-375 cells and 293T were purchased from the American Type Culture Collection (Manassas, VA, USA). Cells were cultured in DMEM medium (Invitrogen Life Technologies, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS; Shanghai ExCell Biology, Inc., Shanghai, China), 100 U/mL penicillin, and 100 $\mu$ g/mL streptomycin. Cultures were maintained at 37 ${}^{\circ}$ C in a humidified air atmosphere with 5% CO ${}_{2}$ .

2.2 Cell transfection

The miR-429 mimics, miR-429 inhibitor, negative control miRNA mimics (mimics NC) and negative control miRNA inhibitor (inhibitor NC) were chemically synthesized by Shanghai GenePharma Co., Ltd. (Shanghai, China).

Some sequences are listed in Table 1. Transient transfection of miR-429 mimics, inhibitor and/or negative control were conducted using Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer’s protocol.

2.3 RTqPCR

The total RNA was extracted from cells using TRIzol ${}^{\@setsize{\scriptsize}{8pt}{\viipt}{\@viipt}\textregistered}$ reagent (Invitrogen Life Technologies), according to the manufacturer’s instructions. To analyze the mRNA expression levels of AKT1, RT was performed using Revert Aid First Strand cDNA synthesis kit (Thermo Fisher Scientific, Vilnius, Lithuania), according to the manufacturer’s instructions. The 20 $\mu$ l PCR mixture contained 10 $\mu$ l 2X QuantiTect SYBR Green PCR Master mix (Takara Bio, Inc.), 1 $\mu$ l cDNA template, 1 $\mu$ l each primer and RNasefree water. The program for polymerase chain reaction (PCR) was: 95 ${}^{\circ}$ C for 15 min, followed by 45 cycles of 94 ${}^{\circ}$ C for 15 sec, 57 ${}^{\circ}$ C for 30 sec and 72 ${}^{\circ}$ C for 30 sec. The expression levels of AKT1 were evaluated using the comparative threshold cycle (Ct) method. GAPDH was used as an internal control. The primers for AKT1 and GAPDH are listed in Table 1. The detection of each sample was performed in triplicate.

2.4 The luciferase reporter assay

The luciferase reporter assay is used to verify whether AKT1 is a direct target of miR-429. Briefly, the 3’-untranslated region (3’-UTR region) of AKT1 with the potential binding sites or mutant sites of miR-429 were generated, followed by fusion into the luciferase reporter vector pGL3-Promoter Vector (Promega, Madison, WI, USA, named as AKT1-WT or AKT1-MUT). The amplification was conducted using primers that listed in Table 1. 293T cells were seeded (10000 cells/well) in a 96 well plate and were co-transfected with miR-429 mimic/miR-negative control, miR-429 inhibitor/inhibitor control and WT/MUT-AKT1-3’-UTR vector. Luciferase activity was measured by using a Luciferase Reporter Assay kit (Promega) in accordance with the manufacturer’s guidance at 48 h after transfection.

2.5 Protein extraction and western blot analysis

Western blot was performed according to manufacturer’s guidance. Briefly, cells were homogenized and total protein were extracted using RIPA buffer, then the extraction of the proteins was detected by Western blot. Proteins were detected with antibodies. The primary antibodies included AKT1 (1:1000; cat; Abcam, Hong Kong, China) and GAPDH (1:1000; cat; Santa Cruz, CA, USA). Goat antirabbit IgG-HRP used as the second antibodies were purchased from Beyotime. GAPDH was used as an internal control.

2.6 In vivo tumor xenograft studies

Six BALB/c-nu mice (6 weeks, 16–18 g), were provided by Shanghai Slac Laboratory Animal Ltd (Shanghai, China). Mice were adapted for 3 days before any experimental procedures. A-375 cells were injected into the underarms of each mouse. Mice received twice intratumoral injection of miR-429 miRNA agomir or agomir negative control each week when the tumor size reached approximately 5 mm $\times$ 5 mm. The tumor size was supervised every week. The tumor volume was calculated using formula V $=$ (a ${}^{2}$ $\times$ b)/2, where “a” represents the width and “b” represents the length, respectively. Animal experiment was approved by the Institutional Ethics Committee on Animal Care and Experimentation at The Guangzhou Medical University of China (approval number: 2017–020).

2.7 Statistical analysis

Statistical significance was analyzed by the $t$ test. Each sample was performed in triplicate. The results were expressed as the means $\pm$ standard deviation. A two-tailed $P<$ 0.05 was considered significant. All statistical analysis was carried out with the SPSS 17.0 statistical software (SPSS, Inc., Chicago, IL, USA).

3. Results

3.1 miR-429 down regulated the expression of AKT1 in the A-375 cell lines

The mRNA and protein analyses were performed to confirm whether the expression of miR-429 affected the expression of AKT1 at the transcriptional or translational levels. Compared to the control group, the cells transfected with the miR-429 mimics suppressed mRNA expression of AKT1 (Fig. 1A), which was consistent with the results from the luciferase report assay. The overexpression of miR-429 decreased AKT1 protein expression dramatically in A-375 cell lines (Fig. 1B).

Figure 1.

A. A-375 cells transfected with miR-429 mimic exhibited decreased mRNA expression levels of AKT1 compared with those transfected with the negative control (NC). B. Overexpression of miR-429 resulted in a decrease in the protein expression levels of AKT1 in the A-375 cell lines. The results represent three independent experiments. ${}^{*}$ , $P\leqslant$ 0.05.

3.2 AKT1 is a direct target of miR-429

Prediction of the miRNA target was performed using computational algorithms, according to the base-pairing rules between the miRNA and mRNA target sites, location of binding sequences within the target’ 3’UTR, and conservation of target binding sequences within associated genomes. In the present study, gene was predicted using the microRNA (http://www. microrna.org/microrna/home.do) computational algorithms (Fig. 2A).

Figure 2.

AKT1 is the target gene of miR-429. A. Putative duplex formation between miR-429 and the AKT1 3’UTR. B. Luciferase reporter constructs containing the 3’UTR of AKT1, together with the miR-429 mimic or negative control; inhibitor or inhibitor NC, were transfected into the 293T cells. After 48 h, luciferase activity was detected. The relative luciferase activity of the reporter, containing the WT 3’UTR was significantly suppressed when miR429 was cotransfected into the 293T cells compared with negative control; containing the WT 3’UTR was significantly promoted when inhibitor was cotransfected into the 293T cells compared with inhibitor NC. C. By contrast, the luciferase activity of the MUT reporter was unaffected. All luciferase assays were repeated three times; UTR, untranslated region; WT, wildtype; MUT, mutant. ${}^{*}P<$ 0.05. n.s., nonsignificant.

To perform luciferase reporter assay for validating whether miR-429 physically interacts with AKT1 mRNA, we constructed two vectors by cloning WT and MUT 3’UTR into pGL3-Promoter Vector. Luciferase reporter constructs containing the 3’UTR of AKT1, together with the miR-429 mimic or negative control; inhibitor or inhibitor NC, were transfected into the 293T cells. After 48 h, luciferase activity was detected. The relative luciferase activity of the reporter, containing the WT 3’UTR was significantly suppressed when miR429 was cotransfected into the 293T cells compared with negative control; containing the WT 3’UTR was significantly promoted when inhibitor was cotransfected into the 293T cells compared with inhibitor NC (Fig. 2B). By contrast, the luciferase activity of the MUT reporter was unaffected (Fig. 2C). All luciferase assays were repeated three times.

3.3 miR-429 suppressed A-375 cells derived xenograft tumor growth in vivo

To confirm whether overexpression of miR-429 could inhibit the growth of tumor, a nude mouse xenograft model was established in this study. As a result, miR-429 inhibited the growth effect of tumor effectively. The size and weight in the nude mice with miR-429 treatment were much lower than these in control mice (Fig. 3A–C).

Figure 3.

Tumor volumes at the indicated dates B and images as well as tumor weight A at day 28 C in the nude mice treated with intratumoral injection of miR-429 agomir or its negative control (NC agomir) for four weeks. The average values are present in the bar graphs (means $\pm$ SD) (H) ( $n=$ 3 for each group). The results represent three independent experiments. ${}^{*}$ , $P\leqslant$ 0.05.

4. Discussion

Melanoma is a highly malignant tumor. Radical surgical removal of the tumor is the one of its main therapies. However, the recurrence rate is still high even after surgery. Therefore, it is urgent to search for alternative treatment for melanoma.

The role of miRNAs has been well studied both in cancer and normal tissues (17–20). MiRNAs are considered as important biomarkers or therapeutic targets for cancers [21]. However, the role of miR-429 it has been found to be controversial. Machackova et al. reported that miR-429 acted as a tumor suppressor through inhibiting loss of E-cadherin in renal cancer cells [22]. miR-429 was also found to be capable of inhibit migration, invasion and proliferation of renal cancer cells via targeting directly Sp1 [15]. Furthermore, miR-429 was related to resistance of chemoradiotherapy of pancreatic cancer through regulation of PDCD4 [23]. In 2018, Xue et al. demonstrated that miR-429 was significantly much lower in HCC tissues and cells compared with normal tissues, meanwhile elevated level of miR-429 could inhibit the metastasis ability in HCC cells through targeting RAB23 [14]. Conversely, Tang et al. reported that MiR-429 enhanced HCC cell invasion and migration through targeting the PTEN/PI3K/AKT/ $\beta$ -catenin axis directly [24]. In human prostate cancer cells, elevated level of miR-429 promotes cell proliferation by targeting p27Kip1 [25].

In the present study, we demonstrated that miR-429 act as a tumor suppressor in melanoma cells. Several signal pathways are involved in miR429 regulated tumor development, such as PDCD4 [23], VEGF [16], and cmyc [26]. It is the first time to demonstrate that AKT1 demonstrated was a target in mediating the anti-tumoral function of miR429.

The phosphoinositide 3kinase (PI3K)/RAC seine/ threonineprotein kinase (AKT)/mechanistic target of rapamycin (mTOR) signaling pathway is frequently dysregulated in several cancers [27, 28]. AKT plays a key role in the PI3K/AKT/mTOR signaling pathway, and it is closely associated with a wide variety of cancer pathophysiology, including EMT, growth, migration metabolism, and angiogenesis [29, 30, 31]. AKT consists of three isoforms (AKT1, AKT2, and AKT3), and the different isoforms act as different roles in cancer pathophysiology. AKT1 can suppress breast cancer cell invasion and migration [32, 33] but accelerated the onset of tumorigenesis [34]. Therefore, knockdown of AKT1 gene inhibited the onset of tumorigenesis [35].

To explore potential effect of miR-429 in melanoma tumorigenesis, four computational algorithms were used to predict the targets of miR-429, which identified AKT1 as a novel target gene. The binding sites of miR-429 on the AKT1 3’UTR were verified using a luciferase reporter assay. In addition, cancer cells transfected with miR-429 mimics showed reduced expression of AKT1 at both mRNA and protein level. The in vitro experiment show that overexpression of miR-429 could obviously enhance the inhibition effect of tumor size and weight in the nude mice. All these findings indicate that AKT1 is a direct target gene of miR-429 in melanoma. Therefore, miR429/AKT1 axis can be a novel marker and therapeutic target in melanoma treatment.

In summary, the present study demonstrates that miR429 acts as a tumor suppressor in melanoma via the regulation of AKT1. This newly underlying association between miR429 and AKT1 may provide a new therapeutic strategy for melanoma.

Footnotes

Acknowledgments

We are indebted to the coworkers, whose names were not included in the author list, but who contributed to this work.

References

Miller

A.J.

and Mihm

M.C.

, Melanoma, N. Engl. J. Med 355 (2006), 51–65.

Perera

R.J.

and Ray

, Epigenetic regulation of miRNA genes and their role in human melanomas, Epigenomics 4 (2012), 81–90.

Bouyssou

J.M.

Manier

Huynh

Issa

Roccaro

A.M.

and Ghobrial

I.M.

, Regulation of microRNAs in cancer metastasis, Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1845 (2014), 255–265.

Schmidt

and Begley

C.G.

, Cancer diagnosis and microarrays, International Journal of Biochemistry & Cell Biology 35 (2003), 119–124.

Zhang

Ding

Zhao

Wang

Jia

Han

Guo

Wang

Jiang

and Cui

, MiRNA expression signature for potentially predicting the prognosis of ovarian serous carcinoma, Tumor Biology 34 (2013), 3501–3508.

Walter

B.A.

Valera

V.A.

Pinto

P.A.

and Merino

M.J.

, Comprehensive microRNA profiling of prostate cancer, Journal of Cancer 4 (2013), 350.

Miao

Peng

Tania

and Zhang

, MicroRNAs in osteosarcoma: diagnostic and therapeutic aspects, Tumour Biology 34 (2013), 2093–2098.

and Li

, Epithelial-mesenchymal transition in human cancer: comprehensive reprogramming of metabolism, epigenetics, and differentiation, Pharmacology & Therapeutics 150 (2015), 33–46.

Chen

Xia

Liu

Lin

and Ge

, KIAA0101, a target gene of miR-429, enhances migration and chemoresistance of epithelial ovarian cancer cells, Cancer Cell International 16 (2016), 74.

10.

Fan

J.Y.

Fan

Y.J.

Wang

X.L.

Xie

Gao

H.J.

Zhang

Liu

and Tang

, miR-429 is involved in regulation of NF-κB activity by targeting IKKβ and suppresses oncogenic activity in cervical cancer cells, Febs Letters 591 (2017), 118–128.

11.

Goeppert

Ernst

Baer

Roessler

Renner

Mehrabi

Hafezi

Pathil

Warth

Stenzinger

Weichert

Bähr

Will

Schirmacher

Plass

and Weichenhan

, Cadherin-6 is a putative tumor suppressor and target of epigenetically dysregulated miR-429 in cholangiocarcinoma, Epigenetics 11 (2016), 780–790.

12.

Xiao

Liu

and Zhou

, miR-200b inhibits migration and invasion in non-small cell lung cancer cells via targeting FSCN1, Molecular Medicine Reports 14 (2016), 1835.

13.

Sheng

Zhang

and Yang

, MicroRNA-429 decreases the invasion ability of gastric cancer cell line BGC-823 by downregulating the expression of heparanase, Experimental and Therapeutic Medicine 15 (2018), 1927–1933.

14.

Xue

and Tian

G.Y.

, MiR-429 regulates the metastasis and EMT of HCC cells through targeting RAB23, Archives of Biochemistry and Biophysics 637 (2018), 48–55.

15.

Niu

Pan

Zhou

Zhang

and Zhou

, Tumor-suppressing effects of microRNA-429 in human renal cell carcinoma via the downregulation of Sp1, Oncol Lett 12 (2016), 2906–2911.

16.

Chen

Jin

Yang

Mao

and Lai

, Tumor suppressive microRNA429 regulates cellular function by targeting VEGF in clear cell renal cell carcinoma, Mol Med Rep 13 (2016), 1361–1366.

17.

Liu

Zhang

Jia

Tan

Jin

and Liu

, miR-494 promotes cell proliferation, migration and invasion, and increased sorafenib resistance in hepatocellular carcinoma by targeting PTEN, Oncology Reports 34 (2015), 1003.

18.

Meng

Tai

Zhao

Zhang

Liu

Yang

Zhang

Feng

and Chen

, Downregulation of miR-33a-5p in hepatocellular carcinoma: a possible mechanism for chemotherapy resistance, Medical Science Monitor 23 (2017), 1295–1304.

19.

Qin

C.Z.

Lou

X.Y.

Q.L.

Cheng

N.Y.

and Zhou

H.H.

, MicroRNA-184 acts as a potential diagnostic and prognostic marker in epithelial ovarian cancer and regulates cell proliferation, apoptosis and inflammation, Die Pharmazie 70 (2015), 668.

20.

Guo

Pang

Gao

Zhao

Zhang

Xuan

and Wang

, MicroRNA-137 chemosensitizes colon cancer cells to the chemotherapeutic drug oxaliplatin (OXA) by targeting YBX1, Cancer Biomarkers 18 (2017), 1–9.

21.

Chan

S.H.

and Wang

L.H.

, Regulation of cancer metastasis by microRNAs, Journal of Biomedical Science 22 (2015), 9.

22.

Machackova

Mlcochova

Stanik

Dolezel

Fedorko

Pacik

Poprach

Svoboda

and Slaby

, MiR-429 is linked to metastasis and poor prognosis in renal cell carcinoma by affecting epithelial-mesenchymal transition, Tumour Biol 37 (2016), 14653–14658.

23.

Jia

Cheng

Zhou

Qian

Liu

and Wang

, MicroRNA-429 sensitizes pancreatic cancer cells to gemcitabine through regulation of PDCD4, Am J Transl Res 9 (2017), 5048–5055.

24.

Tang

Huang

Sui

Yang

Lin

Hou

Chen

Yuan

Wen

Tang

Cao

Chen

and Wang

, MiR-429 increases the metastatic capability of HCC via regulating classic Wnt pathway rather than epithelial-mesenchymal transition, Cancer Lett 364 (2015), 33–43.

25.

Ouyang

Gao

Zhu

Chen

Lin

Wang

Wei

and Zhang

, Downregulation of microRNA-429 inhibits cell proliferation by targeting p27Kip1 in human prostate cancer cells, Molecular Medicine Reports 11 (2015), 1435–1441.

26.

Sun

Wang

Xing

and Wu

, miR-429 modulates the expression of c-myc in human gastric carcinoma cells, European Journal of Cancer 47 (2011), 2552–2559.

27.

Bhaskar

P.T.

and Hay

, The two TORCs and Akt, Developmental Cell 12 (2007), 487–502.

28.

Engelman

J.A.

, Targeting PI3K signalling in cancer: opportunities, challenges and limitations, Nature Reviews Cancer 9 (2009), 550–562.

29.

Tang

Massi

Hemmings

B.A.

Mandalà

Wicki

and Xue

, AKT-ions with a TWIST between EMT and MET, Oncotarget 7 (2016), 62767–62777.

30.

Lao

Zhang

and Gillespie

D.A.

, Akt: a double-edged sword in cell proliferation and genome stability, Journal of Oncology 2012 (2012), 951724.

31.

Manning

B.D.

and Cantley

L.C.

, AKT/PKB signaling: navigating downstream, Cell 129 (2007), 1261–1274.

32.

Chin

Y.R.

and Toker

, The actin-bundling protein palladin is an Akt1-specific substrate that regulates breast cancer cell, Molecular Cell 38 (2010), 333–344.

33.

Liu

Radisky

D.C.

Nelson

C.M.

Zhang

Fata

J.E.

Roth

R.A.

and Bissell

M.J.

, Mechanism of aktl inhibition of breast cancer cell invasion reveals a protumorigenic role for TSC2, Proceedings of the National Academy of Sciences of the United States of America 103 (2006), 4134–4139.

34.

Hutchinson

J.N.

Jin

J.R.

Woodgett

J.R.

and Muller

W.J.

, Activation of Akt-1 (PKB-alpha) can accelerate ErbB-2-Mediated mammary tumorigenesis but suppresses tumor invasion, Cancer Research 64 (2004), 3171–3178.

35.

Maroulakou

I.G.

Oemler

Naber

S.P.

and Tsichlis

P.N.

, Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice, Cancer Research 67 (2007), 167–177.

MicroRNA-429 inhibits cancer cell proliferation and migration by targeting the AKT1 in melanoma

Abstract

Keywords

1. Introduction

Table 1 Primer sequences used in the present study

2.1 Cell culture

2.2 Cell transfection

2.3 RTqPCR

2.4 The luciferase reporter assay

2.5 Protein extraction and western blot analysis

2.6 In vivo tumor xenograft studies

2.7 Statistical analysis

3. Results

3.1 miR-429 down regulated the expression of AKT1 in the A-375 cell lines

Footnotes

Acknowledgments

References

Table 1
Primer sequences used in the present study